Commentary · 21 Feb 2026
Conference abstractPublished 26 Sep 2016
The role of stem-like glioma cells in GBM progression and post-treatment recurrence
Johannes Gutenberg University Medical Centre, Germany
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Glioblastoma multiforme (GBM) is the most malignant intrinsic brain tumor. The current standard of care for newly diagnosed GBMs involves maximum safe resection, radiation therapy and concomitant/adjuvant chemotherapy with DNA alkylating agent temozolimide (TMZ). The efficacy of existing therapies is unsatisfactory with a rather modest survival advantage compared to radiation treatment alone (median survival 14.6 vs. 12.2 months, respectively), <10% of the highest 5-years survival rate and inevitable post-treatment recurrence. Developing effective therapies for GBM previously based on the paradigm for the pathogenesis and therapeutic resistance of this devastating disease is ongoing. A new conception of GBM has emerged after the identification of a distinct population of glioma stem-like cells (GSCs). GSCs are thought to have the highest tumorigenic potential among all cell types comprising the tumor and responsible for tumor growth after treatment. However, there is still considerable uncertainty regarding the precise role of GSCs in the initiation, maintenance and progression of GBM with some fundamental questions remaining. Is there a universal type of stem-like glioma cells? What criteria define glioma cell stemness? How does the degree of glioma cell stemness relate to the clinicopathological criteria of glioma aggressiveness? Our research indicates that, in GBM, the type of cells collectively called GICs comprise heterogeneous subtypes of phenotypically and functionally distinct cells with varying tumorigenic potential. Our findings urge a reconsideration of some of the key assumptions of the GIC paradigm and provide important insights into the roles of different types of stem-like cells in GBM.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Cancer Science & Therapy.
Perspective · 21 Feb 2026
Finding Potential Passerini Adducts for Anticancer Drug Development
Perspective · 21 Feb 2026
Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Invasion
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Ella L Kim”
